FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:808-810 March 18, 1993 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: In his accompanying editorial (Oct. 29 issue),¹ Dr. Growdon cites the minimally positive results with tacrine in the multicenter study by Davis et al.² to argue for the abandonment of "simple replacement" cholinomimetic therapies in favor of promising futuristic restorative approaches. Although new approaches are desperately needed, we must also be diligent in our evaluation of current methods. In our view, the most likely factor responsible for the unimpressive clinical effect of tacrine may be the deletion of the higher doses (120 and 160 mg per day) from the protocol because of their propensity to cause marked . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Fakouhi, T. D., Jhee, S. S., Sramek, J. J., Benes, C., Schwartz, P., Hantsburger, G., Herting, R., Swabb, E. A., Cutler, N. R. (1995). Evaluation of Cycloserine in the Treatment of Alzheimer's Disease. J Geriatr Psychiatry Neurol 8: 226-230 [Abstract]